Literature DB >> 17551540

Repeated lipopolysaccharide (LPS) or cytokine treatments sensitize ethanol withdrawal-induced anxiety-like behavior.

George R Breese1, Darin J Knapp, David H Overstreet, Montserrat Navarro, Tiffany A Wills, Robert A Angel.   

Abstract

Previous investigations demonstrated that repeated stresses before an ethanol exposure sensitize ethanol withdrawal-induced anxiety-like behavior ('anxiety'). In addition to activating the hypothalamic-pituitary-adrenal axis, acute stress also elevates cytokines in brain. Initially, to test possible cytokine involvement in this stress/withdrawal protocol, cytokines were increased in brain with 2 weekly repeated lipopolysaccharide (LPS) administrations (1000 microg/kg) [corrected] (LPS/withdrawal protocol) or with twice weekly intracerebroventricular (i.c.v.) administrations of the cytokines IL-1 beta, CCL2 (MCP-1) or TNFalpha (cytokine/withdrawal protocol) before exposure and withdrawal from a 5-day cycle of chronic ethanol diet. Both protocols sensitized withdrawal-induced anxiety and confirm cytokine involvement in the sensitized anxiety response. Testing of various doses of LPS (16-1000 microg/kg) and TNFalpha (3-100 ng, i.c.v.) demonstrated the dose-related nature of these protocols to sensitize withdrawal-induced anxiety. The sensitized anxiety was not produced by a single 5-day ethanol diet cycle or by repeated LPS or cytokine treatments alone. Likewise, sensitized anxiety in these protocols could not be attributed to differences in ethanol ingestion. When challenged with a subsequent re-exposure to a 5-day ethanol diet cycle 16 days after completion of the LPS/withdrawal or cytokine/withdrawal protocols, an increase in withdrawal-induced anxiety was observed-an indication of induction of an underlying persistent adaptive change. Finally, just as found previously with the stress/withdrawal protocol, administration of the benzodiazepine receptor antagonist flumazenil before the LPS or TNF treatments prevented anxiety sensitization. Together, these findings indicate that increased cytokine activity induces adaptive change that supports sensitization of ethanol withdrawal-induced anxiety that may be linked to GABA(A)-receptor function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17551540      PMCID: PMC2268634          DOI: 10.1038/sj.npp.1301468

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  86 in total

1.  Peripheral and central proinflammatory cytokine response to a severe acute stressor.

Authors:  Kevin A O'Connor; John D Johnson; Michael K Hansen; Julie L Wieseler Frank; Elena Maksimova; Linda R Watkins; Steven F Maier
Journal:  Brain Res       Date:  2003-11-21       Impact factor: 3.252

Review 2.  Neurological basis of drug dependence and its effects on the immune system.

Authors:  Herman Friedman; Toby K Eisenstein
Journal:  J Neuroimmunol       Date:  2004-02       Impact factor: 3.478

3.  Stress sensitization of ethanol withdrawal-induced reduction in social interaction: inhibition by CRF-1 and benzodiazepine receptor antagonists and a 5-HT1A-receptor agonist.

Authors:  George R Breese; Darin J Knapp; David H Overstreet
Journal:  Neuropsychopharmacology       Date:  2004-03       Impact factor: 7.853

4.  A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats.

Authors:  David H Overstreet; Darin J Knapp; Sheryl S Moy; George R Breese
Journal:  Psychopharmacology (Berl)       Date:  2003-04-04       Impact factor: 4.530

Review 5.  Neuroendocrine pharmacology of stress.

Authors:  Gonzalo A Carrasco; Louis D Van de Kar
Journal:  Eur J Pharmacol       Date:  2003-02-28       Impact factor: 4.432

Review 6.  Cytokines, stress and depressive illness: brain-immune interactions.

Authors:  Hymie Anisman; Zul Merali
Journal:  Ann Med       Date:  2003       Impact factor: 4.709

7.  Modulation of multiple ethanol withdrawal-induced anxiety-like behavior by CRF and CRF1 receptors.

Authors:  David H Overstreet; Darin J Knapp; George R Breese
Journal:  Pharmacol Biochem Behav       Date:  2004-02       Impact factor: 3.533

8.  Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity.

Authors:  Akira Nakajima; Kiyofumi Yamada; Taku Nagai; Takehisa Uchiyama; Yoshiaki Miyamoto; Takayoshi Mamiya; Jue He; Atsumi Nitta; Makoto Mizuno; Manh Hung Tran; Aika Seto; Masako Yoshimura; Kiyoyuki Kitaichi; Takaaki Hasegawa; Kuniaki Saito; Yasuhiro Yamada; Mitsuru Seishima; Kenji Sekikawa; Hyoung-Chun Kim; Toshitaka Nabeshima
Journal:  J Neurosci       Date:  2004-03-03       Impact factor: 6.167

9.  Behavioral changes in rats after acute, chronic and repeated administration of interleukin-1beta: relevance for affective disorders.

Authors:  Stefania Bonaccorso; Steven F Maier; Herbert Y Meltzer; Michael Maes
Journal:  J Affect Disord       Date:  2003-11       Impact factor: 4.839

Review 10.  The neurobiology and control of anxious states.

Authors:  Mark J Millan
Journal:  Prog Neurobiol       Date:  2003-06       Impact factor: 11.685

View more
  45 in total

Review 1.  Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse.

Authors:  George R Breese; Rajita Sinha; Markus Heilig
Journal:  Pharmacol Ther       Date:  2010-10-15       Impact factor: 12.310

2.  Intoxication- and withdrawal-dependent expression of central and peripheral cytokines following initial ethanol exposure.

Authors:  Tamara L Doremus-Fitzwater; Hollin M Buck; Kelly Bordner; Laura Richey; Megan E Jones; Terrence Deak
Journal:  Alcohol Clin Exp Res       Date:  2014-08       Impact factor: 3.455

Review 3.  Alcohol use disorder and sleep disturbances: a feed-forward allostatic framework.

Authors:  George F Koob; Ian M Colrain
Journal:  Neuropsychopharmacology       Date:  2019-06-24       Impact factor: 7.853

4.  Ethanol Consumption in Mice Lacking CD14, TLR2, TLR4, or MyD88.

Authors:  Yuri A Blednov; Mendy Black; Julia Chernis; Adriana Da Costa; Jody Mayfield; R Adron Harris
Journal:  Alcohol Clin Exp Res       Date:  2017-02-01       Impact factor: 3.455

Review 5.  The role of neuroimmune signaling in alcoholism.

Authors:  Fulton T Crews; Colleen J Lawrimore; T Jordan Walter; Leon G Coleman
Journal:  Neuropharmacology       Date:  2017-02-01       Impact factor: 5.250

6.  Altered hippocampal synaptic transmission in transgenic mice with astrocyte-targeted enhanced CCL2 expression.

Authors:  Thomas E Nelson; Christine Hao; Jessica Manos; R M Ransohoff; Donna L Gruol
Journal:  Brain Behav Immun       Date:  2011-02-26       Impact factor: 7.217

Review 7.  An Overview and Proposed Research Framework for Studying Co-Occurring Mental- and Physical-Health Dysfunction.

Authors:  Sarah L Hagerty; Jarrod M Ellingson; Timothy B Helmuth; L Cinnamon Bidwell; Kent E Hutchison; Angela D Bryan
Journal:  Perspect Psychol Sci       Date:  2019-06-07

Review 8.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 9.  The neuroimmune transcriptome and alcohol dependence: potential for targeted therapies.

Authors:  Anna Warden; Emma Erickson; Gizelle Robinson; R Adron Harris; R Dayne Mayfield
Journal:  Pharmacogenomics       Date:  2016-12-05       Impact factor: 2.533

10.  Age-related differences in anxiety-like behavior and amygdalar CCL2 responsiveness to stress following alcohol withdrawal in male Wistar rats.

Authors:  Kathryn M Harper; Darin J Knapp; Meredith A Park; George R Breese
Journal:  Psychopharmacology (Berl)       Date:  2016-09-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.